Form 4: Director James M. Daly Executes Equity Transactions at ACAD

Acadia Pharmaceuticals director James M. Daly reported the vesting of restricted stock units and the acquisition of new stock options.

Summary

• Director James M. Daly acquired 8,107 shares of common stock through the vesting of restricted stock units (RSUs) on May 29, 2026.
• Following the transaction, Daly holds 12,148 shares of common stock directly.
• Daly was granted 16,004 stock options with an exercise price of $21.66, vesting quarterly over one year.
• Daly was granted 9,311 additional RSUs, which vest on the earlier of one year from the grant date or the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding director equity compensation with no impact on company operations.

Positives

• Director maintains a direct equity stake of 12,148 shares, aligning interests with shareholders.
• Equity grants serve as a standard retention and incentive mechanism for board members.

Negatives

• None identified; this is a routine disclosure of director compensation and equity movement.

Risks

• Future value of equity grants is subject to market volatility and the company's share price performance.
• Vesting schedules are contingent upon continued service as a director.

Future Outlook

The director has elected to defer receipt of the 9,311 newly granted RSUs until the fifth anniversary of the grant, cessation of board service, or a change in control.

Management Comments

• The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until specific future events occur.

Industry Context

StockSavvy.ai notes that routine equity filings for directors are standard corporate governance practices in the biopharmaceutical sector, reflecting typical board compensation structures rather than strategic shifts.

Comparison to Industry Standards

• The use of RSU and stock option grants for board compensation is consistent with standard practices for mid-cap biotechnology companies.
• The deferral election for RSUs is a common tax and wealth management strategy utilized by corporate directors.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as these are standard director compensation arrangements.

Next Steps

• Quarterly vesting of the 16,004 stock options over the next 12 months.
• Vesting of 9,311 RSUs on the earlier of one year from grant or the next annual meeting.

Key Dates

Keywords

ACAD, Acadia Pharmaceuticals, Form 4, Insider Trading, Director Compensation, Equity Incentive Plan